ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years
Shengnan Li
Matched on ORCID iD 0000-0002-3458-218X; OpenAlex author ID A5100359469. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 7
- Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-025-67197-3↗
- CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism. Co-author DOI 10.1002/advs.202206335↗
- Prognostic Implications of an Autophagy-related Gene Signature in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/coc.0000000000000890↗
- Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.841819↗
- Role of the preoperative circulating tumor DNA KRAS mutation in patients with resectable pancreatic cancer. Co-author DOI 10.2217/pgs-2020-0183↗
- KIF23 enhances cell proliferation in pancreatic ductal adenocarcinoma and is a potent therapeutic target. Co-author DOI 10.21037/atm-20-1970↗
- Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.7150/jca.33767↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chongbiao Huang · 3 shared papers, 2022–2025 · strength 0.47
- Paper Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pan… DOI 10.1038/s41467-025-67197-3↗
- Paper Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer. DOI 10.3389/fonc.2022.841819↗
- Paper CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Ind… DOI 10.1002/advs.202206335↗
- Weishuai Liu · 3 shared papers, 2022–2025 · strength 0.47
- Paper Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pan… DOI 10.1038/s41467-025-67197-3↗
- Paper Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer. DOI 10.3389/fonc.2022.841819↗
- Paper CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Ind… DOI 10.1002/advs.202206335↗
- Jihui Hao · 3 shared papers, 2022–2025 · strength 0.47
- Paper Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pan… DOI 10.1038/s41467-025-67197-3↗
- Paper Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer. DOI 10.3389/fonc.2022.841819↗
- Paper CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Ind… DOI 10.1002/advs.202206335↗
- Chuntao Gao · 3 shared papers, 2020–2022 · strength 0.41
- Paper Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer. DOI 10.3389/fonc.2022.841819↗
- Paper KIF23 enhances cell proliferation in pancreatic ductal adenocarcinoma and is a potent therapeutic target. DOI 10.21037/atm-20-1970↗
- Paper Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma. DOI 10.7150/jca.33767↗
- Chao Wu · 2 shared papers, 2023–2025 · strength 0.33
- Paper Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pan… DOI 10.1038/s41467-025-67197-3↗
- Paper CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Ind… DOI 10.1002/advs.202206335↗
- Xiaojie Li · 2 shared papers, 2020–2021 · strength 0.28
- Tiansuo Zhao · 2 shared papers, 2020–2022 · strength 0.28
- Wei-Shuai Liu · 1 shared paper, 2022 · strength 0.20
- Kun Wang · 1 shared paper, 2022 · strength 0.20
- Song Gao · 1 shared paper, 2025 · strength 0.18
- Yiping Zou · 1 shared paper, 2025 · strength 0.18
- Jun Yu · 1 shared paper, 2025 · strength 0.18
- Xinyue Liu · 1 shared paper, 2025 · strength 0.18
- Yongjie Xie · 1 shared paper, 2025 · strength 0.18
- Yukuan Feng · 1 shared paper, 2025 · strength 0.18
- Chao Yang · 1 shared paper, 2025 · strength 0.18
- Yu Xu · 1 shared paper, 2021 · strength 0.15
- Xin Li · 1 shared paper, 2021 · strength 0.15
- He Ren · 1 shared paper, 2021 · strength 0.15
- Bo Tang · 1 shared paper, 2023 · strength 0.14
- Peng Xie · 1 shared paper, 2023 · strength 0.14
- Xiaozhou Yu · 1 shared paper, 2023 · strength 0.14
- Yizhang Zhou · 1 shared paper, 2020 · strength 0.13
- Xiaofan Guo · 1 shared paper, 2020 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.